Plasma pro-opiomelanocortin fragments and adrenal steroids following administration of metyrapone to normal and hirsute women.
The present study was undertaken to characterize further the adrenal abnormalities in the polycystic ovary syndrome (PCOS) and idiopathic hirsutism (IH). We have previously reported the close association of elevated estrone levels with amenorrhea in hyperandrogenemic patients. In addition we have suggested that high estrone levels in PCOS occur as a consequence of the provision of excess substrate, androstenedione, for conversion to estrone. In the present study plasma estrone levels rose following endogenous adrenal stimulation induced using metyrapone; the highest plasma estrone levels achieved were seen in patients with PCOS and occurred later than peak androstenedione levels. These findings are consistent with the hypothesis that elevated estrone levels occurring in PCOS may arise as a consequence of increased adrenal androgen secretion. In addition, we have examined ACTH and other pro-opiomelanocortin (POMC) fragments in an attempt to identify a factor responsible for the excessive adrenal androgen secretion occurring in hirsute patients. Plasma levels of ACTH, and of immunoreactive beta-endorphin and h-lipotropin were not elevated when androgen levels were raised prior to therapy, although these POMC fragments, and also the 16K fragment, rose in response to metyrapone treatment as did androgen levels. Following treatment with dexamethasone there was more profound suppression of the 16K, beta-endorphin and h-lipotropin responses to metyrapone stimulation, than of the ACTH response, as indicated by decreased POMC-fragment/ACTH ratios; this parallels the dissociation of cortisol from androgens in hirsute patients under similar conditions. However, we have not identified a POMC fragment which consistently parallels changes in androgen levels in patients with idiopathic hirsutism or PCOS.
Cunningham
S K
SK
Department of Endocrinology, St. Vincent's Hospital, Dublin, Ireland.
Loughlin
T
T
Bertagna
X
X
Girard
F
F
McKenna
T J
TJ
D000284:Administration, Oral; D000293:Adolescent; D000311:Adrenal Glands / Q000187:drug effects; D000324:Adrenocorticotropic Hormone / Q000097:blood*; D000328:Adult; D000735:Androstenedione / Q000097:blood; D003350:Cortodoxone / Q000097:blood; D003907:Dexamethasone / Q000627:therapeutic use; D004958:Estradiol / Q000097:blood; D004970:Estrone / Q000097:blood; D005260:Female; D006628:Hirsutism / Q000188:drug therapy*; D006801:Humans; D008797:Metyrapone / Q000008:administration & dosage* / Q000494:pharmacology; D010446:Peptide Fragments / Q000097:blood*; D011333:Pro-Opiomelanocortin / Q000097:blood*; D013739:Testosterone / Q000097:blood; D001615:beta-Endorphin / Q000097:blood* / Q000276:immunology; D008083:beta-Lipotropin / Q000097:blood* / Q000276:immunology
D010446:Peptide Fragments; D004970:Estrone; D013739:Testosterone; D000735:Androstenedione; D004958:Estradiol; D001615:beta-Endorphin; D011333:Pro-Opiomelanocortin; D003907:Dexamethasone; D000324:Adrenocorticotropic Hormone; D008083:beta-Lipotropin; D003350:Cortodoxone; D008797:Metyrapone